Poster – R. Blumenthal, M. Spellman. A randomized trial to determine the efficacy and safety of FCX-007 in the treatment of recessive dystrophic epidermolysis bullosa (DEFI-RDEB). Presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy, Washington, DC, May 17, 2022.
Poster – M. P. Marinkovich, K. J. Sridhar, S. Bagci, J. A. M. Dolorito, D. R. Keene, M. Yonchek, R Blumenthal, M Spellman, MD. The treatment of wounds associated with recessive dystrophic epidermolysis bullosa with local injections of gene-corrected, collagen VII-expressing autologous human dermal fibroblasts. Presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy, Washington, DC, May 17, 2022.
Poster – M. P. Marinkovich, MD, A. Lane, MD, K. Sridhar, PhD, D. Keene, BS, A. Malyala, PhD, M. Spellman, MD, and J. Maslowski, MS. A Phase 1/2 Study of Genetically-Corrected, Collagen VII Expressing Autologous Human Dermal Fibroblasts Injected into the Skin of Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB). Presented at EB 2020 Congress, London, United Kingdom, January 2020.
Poster – M. P. Marinkovich, MD, N. Ehsani-Chimeh, MD, N. Nguyen, S. Moncrief, PhD, V. K. Dailey, M. Chakiath, A. Elayadi, PhD, S. Krishnan, MS, and J. Maslowski, MS. Pre-Clinical Development of a Genetically-Modified Human Dermal Fibroblast (FCX-007) for the Treatment of Recessive Dystrophic Epidermolysis Bullosa. Presented at the American Society of Human Genetics Annual Meeting, Baltimore, Maryland, October 8, 2015.
Poster – V.K. Dailey, M. Chakiath, A. Elayadi, PhD, S. Krishnan, MS, J. Maslowski, MS, M. P. Marinkovich, MD. Development of a Genetically-Modified Human Dermal Fibroblast for the Treatment of Recessive Dystrophic Epidermolysis Bullosa. Presented at the European Society of Human Genetics, Glasgow, Scotland, United Kingdom, June 8, 2015.
Photo: Courtesy of debra–The Dystrophic Epidermolysis Bullosa Research Association of America. Used with permission.
